You might also like
Johnson & Johnson (JNJ) is a global healthcare company that operates through two main business segments: Innovative Medicine and MedTech. The company focuses on developing and distributing therapeutic products in areas such as Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases, as well as medical devices used in Orthopaedics, Surgery, Interventional Solutions, and Vision fields . Johnson & Johnson's products are distributed to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use .
- Innovative Medicine - Develops and distributes therapeutic products in areas including Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Key products include STELARA and DARZALEX, which are significant contributors to the company's revenue .
- MedTech - Offers medical devices and solutions used in Orthopaedics, Surgery, Interventional Solutions, and Vision fields. These products are primarily used by healthcare professionals such as physicians and nurses .
-
Can you elaborate on the impact of patient mix issues on U.S. sales of TREMFYA and STELARA, and whether this is specific to Johnson & Johnson or indicative of broader market trends?
-
Given the challenges posed by volume-based procurement and the anti-corruption campaign in China, how do you plan to mitigate the headwinds facing your MedTech business in the Asia Pacific region, and what are your expectations for 2025?
-
With the upcoming biosimilar competition for STELARA, how confident are you that TREMFYA and JNJ-2113 can replace the sales loss and take market share from entrenched competitors in the immunology space?
-
In light of the competitive pressures in the electrophysiology market and the delayed U.S. launch of VARIPULSE, how do you intend to regain share, and what are your expectations for your EP business in 2025?
-
Considering the increased R&D investments and recent acquisitions, can you provide more details on where these elevated investments are being directed and how they will impact your operating margins and growth targets for the coming year?
Recent developments and announcements about JNJ.
Financial Reporting
- Reported Sales: $22.5 billion, a 5.3% increase compared to Q4 2023, with operational growth of 6.7% and adjusted operational growth of 5.7%.
- Earnings Per Share (EPS):
- Reported EPS: $1.41, down 17.1% year-over-year.
- Adjusted EPS: $2.04, down 10.9% year-over-year.
- Net Earnings: $3.43 billion, a 17.0% decrease compared to Q4 2023.
- Reported Sales: $88.8 billion, a 4.3% increase compared to 2023, with operational growth of 5.9% and adjusted operational growth of 5.4%.
- Earnings Per Share (EPS):
- Reported EPS: $5.79, up 11.3% year-over-year.
- Adjusted EPS: $9.98, a slight increase of 0.6% year-over-year.
- Net Earnings: $14.07 billion, a 5.6% increase compared to 2023.
-
Innovative Medicine Segment:
- Worldwide operational sales (excluding COVID-19 vaccine) grew 7.5%.
- Strong performance from DARZALEX, ERLEADA, CARVYKTI, and TREMFYA.
- Neuroscience products like SPRAVATO also contributed significantly.
-
MedTech Segment:
- Worldwide operational sales grew 6.2%, driven by electrophysiology products, Abiomed, and wound closure products.
- Operational Sales Growth: Expected between 2.5% and 3.5%.
- Adjusted Operational EPS: Projected between $10.75 and $10.95, reflecting a strong growth of 8.7% at the midpoint.
- Significant progress in the pipeline, including:
- RYBREVANT + LAZCLUZE overall survival data.
- Initiation of TAR-200 submission.
- Approval of the OTTAVA general surgery robotic system.
- U.S. Sales: $13.2 billion in Q4 2024, a 10.0% increase year-over-year.
- International Sales: $9.3 billion in Q4 2024, a slight decline of 0.7% year-over-year.
Earnings Report
Johnson & Johnson (JNJ) Q4 and Full-Year 2024 Earnings Results
Johnson & Johnson (JNJ) has released its Q4 2024 and full-year 2024 earnings results, showcasing strong financial performance and significant growth in key areas. Below are the highlights:
Q4 2024 Financial Highlights
Full-Year 2024 Financial Highlights
Key Growth Drivers
2025 Guidance
Pipeline and Innovation
Regional Performance
CEO Statement
Joaquin Duato, Chairman and CEO, highlighted 2024 as a transformative year for JNJ, emphasizing the company's focus on innovation and improving care for diseases with high unmet needs, such as multiple myeloma, lung cancer, and heart failure.
Conclusion
Johnson & Johnson's 2024 results reflect robust growth across its segments, driven by innovation and strategic investments. The company is well-positioned for continued success in 2025, with strong guidance and a promising pipeline.
, , ,